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Background and aims: This study was designed to assess the effects of combined vitamin D and probiotic
supplementation on metabolic status and pregnancy outcomes in women with gestational diabetes
(GDM).
Methods: This randomized, double-blind, placebo-controlled clinical trial was performed in 87 women
with GDM. Patients were randomly assigned three groups to receive either vitamin D (50,000 IU/every 2
weeks) plus probiotic (8  109 CFU/day) (n ¼ 30), probiotic (8  109 CFU/day) (n ¼ 29) or placebo
(n ¼ 28) for 6 weeks.
Results: Vitamin D and probiotic co-supplementation signiﬁcantly reduced fasting plasma glucose
(b 10.99 mg/dL; 95% CI, 14.26, 7.73; P < 0.001), serum insulin levels (b 1.95 mIU/mL; 95%
CI, 3.05, 0.84; P ¼ 0.001) and homeostasis model of assessment-insulin resistance (b 0.76; 95%
CI, 1.06, 0.45; P < 0.001), and signiﬁcantly increased the quantitative insulin sensitivity check index
(b 0.01; 95% CI, 0.008, 0.03; P ¼ 0.001) compared with the placebo. In addition, vitamin D and probiotic
co-supplementation resulted in a signiﬁcant reduction in triglycerides (b 37.56 mg/dL; 95%
CI, 51.55, 23.56; P < 0.001), VLDL- (b 7.51 mg/dL; 95% CI, 10.31, 4.71; P < 0.001), HDL-/total
cholesterol ratio (b 0.52; 95% CI, 0.79, 0.24; P < 0.001), high sensitivity C-reactive protein
(b 1.80 mg/L; 95% CI, 2.53, 1.08; P < 0.001) and malondialdehyde (b 0.43 mmol/L; 95%
CI, 0.77, 0.09; P ¼ 0.01); also, a signiﬁcant rise in HDL-cholesterol (b 4.09 mg/dL; 95% CI, 1.11, 7.08;
P ¼ 0.008) and total antioxidant capacity (TAC) levels (b 97.77 mmol/L; 95% CI, 52.34, 143.19; P < 0.001)
were observed compared with the placebo. Vitamin D and probiotic co-supplementation did not change
other metabolic parameters. Vitamin D and probiotic co-supplementation signiﬁcantly decreased tri-
glycerides (P ¼ 0.02), VLDL-cholesterol (P ¼ 0.02) and hs-CRP (P ¼ 0.01), and signiﬁcantly increased TAC
(P ¼ 0.006) and total glutathione levels (P ¼ 0.04) compared with only probiotic group.
Conclusions: In conclusion, vitamin D and probiotic co-supplementation in women with GDM had
beneﬁcial effects on metabolic status.
This trial was registered at www.irct.ir as IRCT2017060-75623N119.
© 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
Gestational diabetes mellitus (GDM) which is deﬁned as glucose
intolerance, initially diagnosed during pregnancy accounts for thefor Clinical Nutrition and Metabol
he effects of vitamin D and p
n gestational diabetes: A ranmost common metabolic disorder among pregnant women [1].
There are different modiﬁable and non-modiﬁable factors which
increases the risk of GDM [2]. Gestational Diabetes Mellitus might be
signiﬁcantly associated with multiple adverse outcomes of preg-
nancy including cesarean section, macrosomia, large for gestational
age, and preterm birth, inﬂuencing mother and offspring's health
status in later life [3]. Recent evidence has shown that intrauterineism. All rights reserved.
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crease the chance of DNAdamage in human stem cell, contributing to
increased susceptibility to chronic disease in adulthood [4].
Nowadays, it became obvious that vitamin D deﬁciency is
correlated with increased risk of GDM [5] and signiﬁcant lower of
25-hydroxy vitamin D (25OHD) concentrations were reported in
these patients [6,7]. In addition, the relation between low levels of
25OHD and some pregnancy complication is documented in pre-
vious studies [8]. On the other hand, rising evidence indicated a
change in gut microbiota composition during pregnancy [9]
especially in women with GDM [10]. Some studies have sug-
gested that vitamin D treatment may improve insulin resistance
and lipid inﬁltration to the placenta by suppressing mammalian
target of rapamycin signaling in women with GDM [11]. Recently,
there is evidence to show co-supplementation of vitamin D and
probiotic is better work compared with only vitamin D or pro-
biotic supplementation. Probiotics may alter the composition of
the microbiota in the gastrointestinal tract through producing
antimicrobial substances, which in turn growth and inactivating
toxins of pathogenic bacteria [12]. Aside from targeted antimi-
crobial therapy, probiotics may support colonization resistance
through pathways, including increasing mucus production and
competition for receptors [13]. On the other hand, probiotic may
increase gene expression of vitamin D receptor in the intestinal
cells [14]. In a study conducted by Jones et al. [15], supplemen-
tation with probiotic Lactobacillus reuteri in hypercholesterolemic
adults for 9 weeks signiﬁcantly increased 25OHD concentrations.
In addition, vitamin D supplementation may modulate gut
microbiota through the regulation of the host immune response
[16]. Also, vitamin D supplementation indirectly regulates the
microbiome to maintain tolerance in the gastrointestinal tract
[17]. Vitamin D administration might be a way to manipulate the
composition of the bacterial microbiome [17].
This evidence shows the importance of vitamin D and probiotics
co-supplementation. Therefore, we conducted this investigation to
evaluate the effects of vitamin D and probiotics co-supplementation
on metabolic proﬁles, biomarkers of inﬂammation and oxidative
stress and pregnancy outcomes in women with GDM.
2. Subjects and methods
2.1. Participants
This study was a randomized, double-blind, placebo-controlled
clinical trial, registered in the Iranian registry of clinical trials (http://
www.irct.ir:IRCT201706075623N119), performed at a gynecology
clinic afﬁliated to Arak University of Medical Sciences (AUMS), Arak,
Iran, between May 2017 to January 2018. Eligible subjects were pri-
migravida, aged 18e40 years (at weeks 24e28 of gestation) who
were diagnosed with GDM by a “one-step” 2-h 75-g oral glucose
tolerance test based on the AmericanDiabetes Association guidelines
[18]. The study was approved by the ethics committee of Arak Uni-
versity ofMedical Sciences (AUMS) and voluntarily informed consent
was taken from all participants prior to the initiation of the trial.
Exclusion criteria included taking vitamin D, probiotic and/or sym-
biotic supplements during the last 3 months prior to the interven-
tion, insulin therapy during the intervention, pre-eclampsia,
eclampsia, hypo and hyperthyroidism, and smokers.
2.2. Study design
Firstly, all women were matched for BMI and age. They were
then randomly allocated into three groups to receive either
8  109 CFU/g probiotic containing Lactobacillus acidophilus, Biﬁ-
dobacterium biﬁdum, L. reuteri, and Lactobacillus fermentum (eachPlease cite this article as: Jamilian M et al., The effects of vitamin D and p
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8  109 CFU/g probiotic containing L. acidophilus, B. biﬁdum, L.
reuteri, and L. fermentum (each 2 109) (n¼ 30) or placebo (n¼ 27)
for 6 weeks. Although, the duration of interventionwas 6 weeks, all
women were followed up until the delivery. Vitamin D, probiotic
and its placebos (parafﬁn and starch, respectively) were produced
by Zahravi Pharmaceutical Company (Tabriz, Iran), LactoCare®,
Zisttakhmir Company (Tehran, Iran) and Barij Essence Pharma-
ceutical Company (Kashan, Iran), respectively. They were
completely identical in terms of their appearance, color, shape, size,
smell and taste and packaging. Random assignment was conducted
using computer-generated numbers. Randomization and allocation
concealment was carried out by a trained staff at the gynecology
clinic, about the researchers and participants. All study participants
followed the standard pregnancy protocol in Iran, consuming 1000
IU vitamin D3 and 400 mg/day vitamin B9, from the beginning of
pregnancy, and 60 mg/day ferrous sulfate, from the second
trimester. The compliance rate was assessed by quantifying serum
25(OH) vitamin D levels. Intake of the probiotic, vitamin D3, and
placebo capsules was monitored through asking participants to
return the medication containers. To increase compliance rate, all
patients received brief daily cell phone reminders to take the
supplements. All patients were advised to maintain their routine
dietary habits without any major changes in lifestyle factors mainly
physical activity levels. All patients completed 3-day food records
and three physical activity measures as metabolic equivalents
(METs) at weeks 0, 3, 6 of the treatment.
2.3. Assessment of anthropometric parameters
A trained staff at the maternity clinic took anthropometric
measurements at baseline and 6 weeks following the intervention.
Height and weight (Seca, Hamburg, Germany) were measured
while the participants wore light clothing and no shoes. BMI was
calculated as weight in kg divided by height in meters squared.
2.4. Clinical assessment
Polyhydramnios was diagnosed using the sonographic estima-
tion method at post-intervention. On the basis of this measure-
ment, polyhydramnios was deﬁned as an amniotic ﬂuid index (AFI)
in excess of 25 cm. Preterm delivery was deﬁned as delivery
occurred at <37 weeks of pregnancy and newborn's macrosomia
was deﬁned as birth weight of >4000 g.
2.5. Assessment of biochemical variables
Markers of insulin metabolism were considered as primary
outcomes and lipid proﬁles, biomarkers of inﬂammation and
oxidative stress were considered as secondary outcomes. Ten
milliliters fasting blood samples were collected at the beginning
and 6-week after the intervention at Arak reference laboratory
and centrifuged to separate serum. Serum 25-hydroxyvitamin D
concentrations were measured using an ELISA kit (IDS, Boldon,
UK) with inter- and intra-assay coefﬁcient of variations (CVs)
below 7%. Serum insulin concentrations were quantiﬁed by the
use of an ELISA kit (DiaMetra, Milano, Italy) with inter- and intra-
assay coefﬁcient variances (CVs) of below 5%. The homeostasis
model of assessment-insulin resistance (HOMA-IR), and the
quantitative insulin sensitivity check index (QUICKI) were deter-
mined according to the standard formula [19]. Enzymatic kits
(Pars Azmun, Tehran, Iran) were used to quantify fasting plasma
glucose (FPG), serum triglycerides, VLDL-, total-, LDL- and HDL-
cholesterol concentrations with inter- and intra-assay CVs below
5%. Serum hs-CRP concentrations were determined by commercialrobiotic co-supplementation on glucose homeostasis, inﬂammation,
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CVs below 7%. The plasma nitric oxide (NO) using Griess method
[20], total antioxidant capacity (TAC) by the method of ferric
reducing antioxidant power developed by Benzie and Strain. [21],
total glutathione (GSH) using the method of Beutler et al. [22] and
MDA concentrations by the thiobarbituric acid reactive substances
spectrophotometric test [23] concentrations were determined by
the thiobarbituric acid reactive substances spectrophotometric
test with inter- and intra-assay CVs below 5%. Newborns’ hyper-
bilirubinemia was considered when the total serum bilirubin
levels were at 15 mg/dL (257 mmol/L) or more among infants
who were 25e48 h old, 18 mg/dL (308 mmol/L) in infants who
were 49e72 h old, and 20mg/dL (342 mmol/L) in infants older than
72 h [24].2.6. Sample size
To calculate the sample size, we used the standard formula
suggested for parallel clinical trials by considering type one error
(a) of 0.05 and type two error (b) of 0.20 (power ¼ 80%). Based on a
previous study [25], we used a standard deviation (SD) of 1.41 and a
difference in mean (d) of 1.14, considering HOMA-IR as the key
variable. Based on this, we needed 25 persons in each group.
Assuming 20% dropouts in each group, the ﬁnal sample size was
determined to be 30 persons per group.2.7. Statistical analysis
The normality of model residual was tested using the
KolmogoroveSmirnov test. Anthropometric measures and dietary
intakes were compared among the three groups, using ANOVA test
with Bonferoni post hoc pair-wise comparisons. Multiple linear
regression models were used to assess treatment effects on study
outcomes after adjusting for baseline values of each biochemical
variables. The effect sizes were presented as the mean differences
with 95% conﬁdence intervals. Differences in proportions were eval-
uated by Fisher's exact test. The P-value of<0.05 were consideredFo
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Package for Social Scienceversion 18 (SPSS Inc., Chicago, Illinois, USA).
3. Results
Among individuals in the probiotic group, 2 persons [insulin
therapy (n ¼ 1) and hospitalization (n ¼ 1)] were excluded. The
exclusions in the placebo group were also 3 women [hospitaliza-
tion (n ¼ 1) and insulin therapy (n ¼ 2)]. Finally, 87 participants
[vitamin D plus probiotic (n ¼ 30), probiotic (n ¼ 29) and placebo
(n ¼ 28)] completed the trial (Fig. 1). On average, the rate of
compliance in our study was high, such that 100% of supplements
and placebos were taken throughout the study in three groups.
Mean age, height, weight and BMI at baseline and after the 6-
week treatment were not statistically different between treat-
ments and placebo groups (Table 1).
We observed no significant changes in macro- and micro-
nutrients among the three groups (Table 2).
After the 6-week treatment, vitamin D and probiotic co-
supplementation signiﬁcantly reduced FPG (b 10.99 mg/dL; 95%
CI, 14.26, 7.73; P < 0.001), serum insulin levels (b 1.95 mIU/mL;
95% CI, 3.05, 0.84; P ¼ 0.001) and HOMA-IR (b 0.76; 95%
CI, 1.06, 0.45; P < 0.001), and signiﬁcantly increased QUICKI
(b 0.01; 95% CI, 0.008, 0.03; P ¼ 0.001) compared with the placebo
(Table 3). In addition, vitamin D and probiotic co-supplementation
resulted in a signiﬁcant reduction in triglycerides (b 37.56 mg/dL;
95% CI, 51.55, 23.56; P < 0.001), VLDL- (b 7.51 mg/dL; 95%
CI, 10.31, 4.71; P < 0.001), HDL-/total cholesterol ratio (b 0.52;
95% CI, 0.79, 0.24; P < 0.001), hs-CRP (b 1.80 mg/L; 95%
CI, 2.53, 1.08; P < 0.001) and MDA (b 0.43 mmol/L; 95%
CI, 0.77, 0.09; P ¼ 0.01); also, a signiﬁcant rise in HDL-
cholesterol (b 4.09 mg/dL; 95% CI, 1.11, 7.08; P ¼ 0.008) and TAC
levels (b 97.77 mmol/L; 95% CI, 52.34, 143.19; P < 0.001) were
observed compared with the placebo. Vitamin D and probiotic co-
supplementation did not change other metabolic parameters.
Probiotic supplementation resulted in a signiﬁcant reduction in
FPG (b8.60mg/dL; 95% CI,11.96,5.24; P < 0.001), insulin levels
(b 1.34 mIU/mL; 95% CI, 2.46, 0.22; P ¼ 0.01) and HOMA-IRw-up (n=1)
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Table 1
General characteristics of study participants.a
Placebo group (n ¼ 28) Probiotic group (n ¼ 29) Vitamin D plus probiotic group (n ¼ 30) Pb
Age (y) 29.9 ± 3.7 31.2 ± 5.9 28.9 ± 6.1 0.28
Height (cm) 162.0 ± 5.8 162.8 ± 4.7 160.8 ± 5.3 0.36
Weight at study baseline (kg) 72.0 ± 7.7 70.0 ± 12.5 71.9 ± 12.1 0.74
Weight at end-of-trial (kg) 73.8 ± 7.7 71.7 ± 12.4 73.6 ± 12.1 0.72
Weight change (kg) 1.8 ± 0.7 1.7 ± 0.6 1.8 ± 0.8 0.86
BMI at study baseline (kg/m2) 27.5 ± 3.3 26.4 ± 4.2 27.8 ± 4.9 0.37
BMI at end-of-trial (kg/m2) 28.2 ± 3.3 27.0 ± 4.1 28.5 ± 4.9 0.35
BMI change (kg/m2) 0.7 ± 0.3 0.6 ± 0.2 0.7 ± 0.3 0.78
MET-h/day at study baseline 25.8 ± 1.1 25.3 ± 1.4 25.2 ± 1.3 0.31
MET-h/day at end-of-trial 25.4 ± 1.1 24.9 ± 1.5 24.8 ± 1.4 0.27
MET-h/day change 0.4 ± 0.3 0.4 ± 0.2 0.4 ± 0.2 0.81
a Data are means ± SDs.
b Obtained from ANOVA test. METs, metabolic equivalents.
Table 2
Mean dietary intakes of study participants at baseline, weeks 3 and 6 of the study.a
Placebo group (n ¼ 28) Probiotic group (n ¼ 29) Vitamin D plus probiotic group (n ¼ 30) Pb
Energy (kcal/d) 2201 ± 165 2164 ± 220 2196 ± 192 0.73
Carbohydrates (g/d) 322.8 ± 41.9 313.2 ± 43.8 316.4 ± 42.9 0.69
Protein (g/d) 82.2 ± 16.4 83.2 ± 13.8 85.5 ± 17.3 0.71
Fat (g/d) 80.9 ± 16.9 80.5 ± 10.2 82.1 ± 15.6 0.90
SFA (g/d) 23.0 ± 5.6 24.8 ± 5.0 24.9 ± 6.6 0.37
PUFA (g/d) 27.9 ± 6.4 24.7 ± 5.8 26.5 ± 7.4 0.20
MUFA (g/d) 21.5 ± 6.4 22.0 ± 5.4 21.7 ± 5.8 0.93
Cholesterol (mg/d) 184.2 ± 124.3 233.3 ± 120.3 215.8 ± 133.6 0.33
TDF (g/d) 17.9 ± 4.9 18.5 ± 5.2 18.5 ± 4.1 0.86
Magnesium (mg/d) 273.6 ± 60.8 273.6 ± 69.7 270.7 ± 70.3 0.98
Zinc (mg/d) 9.5 ± 2.8 10.2 ± 2.2 10.4 ± 3.1 0.44
Manganese (mg/d) 2.2 ± 0.8 2.1 ± 0.8 2.2 ± 1.0 0.86
Iron (mg/d) 14.9 ± 3.1 14.6 ± 3.2 14.5 ± 3.2 0.88
MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; TDF, total dietary ﬁber.
a Data are means ± SDs.
b Obtained from ANOVA test.
M. Jamilian et al. / Clinical Nutrition xxx (xxxx) xxx4(b 0.54; 95% CI, 0.84, 0.23; P < 0.001) compared with the
placebo (Table 3). In addition, probiotic supplementation was
associated with a signiﬁcant reduction in triglycerides
(b 21.73 mg/dL; 95% CI, 35.78, 7.69; P ¼ 0.003), VLDL-
cholesterol (b 4.34 mg/dL; 95% CI, 7.15, 1.53; P ¼ 0.003), hs-
CRP (b 1.36 mg/L; 95% CI, 2.07, 0.64; P < 0.001) and MDA
levels (b 0.50 mmol/L; 95% CI, 0.85, 0.16; P ¼ 0.005) compared
with the placebo. Probiotic supplementation did not affect other
metabolic variables. Vitamin D and probiotic co-supplementation
signiﬁcantly decreased triglycerides (b 15.82 mg/dL; 95%
CI, 29.66, 1.98; P ¼ 0.02), VLDL-cholesterol (b 3.16 mg/dL; 95%
CI, 5.93, 0.39; P ¼ 0.02) and hs-CRP (b 0.32 mg/L; 95%
CI, 0.60, 0.05; P ¼ 0.01), and signiﬁcantly increased TAC (b
63.26 mmol/L; 95% CI, 18.25, 108.26; P ¼ 0.006) and GSH levels (b
53.61 mmol/L; 95% CI, 1.56, 105.67; P ¼ 0.04) compared with only
probiotic group.
Co-supplementation with vitamin D and probiotic had a lower
incidence of hyperbilirubinemiain newborns (10.0% vs. 13.8% and
35.7%, P ¼ 0.03) and newborns' hospitalization (10.0% vs. 10.3% and
32.1%, P ¼ 0.04) compared with only probiotic and placebo,
respectively (Table 4). Co-supplementation with vitamin D and
probiotic did not affect other pregnancy outcomes.
4. Discussion
In the current study, we evaluated the effects of a 6-week
vitamin D plus probiotic supplementation compared with only
probiotic and placebo on metabolic responses and pregnancy out-
comes in women with GDM. Our data revealed that vitamin D and
probiotic co-supplementation led to signiﬁcant improvements inPlease cite this article as: Jamilian M et al., The effects of vitamin D and p
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cholesterol, and hs-CRP, TAC and MDA levels, incidence of new-
born's hyperbilirubinemia and newborns' hospitalization, but did
not affect other metabolic proﬁles and pregnancy outcomes.
4.1. Effects on glycemic control and lipid proﬁles
GDM women are susceptible to metabolic disorders, including
abnormal glucose and lipid metabolism, and inﬂammation and
oxidative damage. In the present study, we found that vitamin D and
probiotic co-administration, comparedwith theplacebo, signiﬁcantly
reduced FPG, serum insulin values and HOMA-IR, and signiﬁcantly
increased QUICKI in women with GDM. In line with our ﬁndings,
probiotic consumption has been reported to reduce insulin resistance
inpatientswithGDM[26] andnon-alcoholic fatty liverdisease [27]. In
addition, our recent study showed that combined vitamin D and
probiotic supplementation in diabetic subjects with coronary heart
disease for 12 weeks improved insulin concentrations, HOMA-IR and
QUICKI, while did not change FPG [28]. In contrast to our ﬁndings,
Lindsay et al. [29] reported no beneﬁcial effects on glycemic control
after probiotic intake in women with GDM. Furthermore, a 4-week
supplementation with high-dose vitamin D did not affect insulin
secretion and insulin sensitivity [30]. Insulin dysfunction occurs in
GDMmight both progress to T2DM in later life and leads to neonatal
complications [31]. It also can cause adverse long-term maternal
outcomes such as increased perinatal morbidity such asmacrosomia,
birth trauma and pre-eclampsia [32].
Our ﬁndings indicated that vitamin D and probiotic co-
supplementation, compared with the placebo, signiﬁcantly
decreased serum triglycerides, VLDL-, and total-/HDL-cholesterolrobiotic co-supplementation on glucose homeostasis, inﬂammation,
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Table 3
Metabolic proﬁles, biomarkers of inﬂammation and oxidative stress at study baseline and after the 6-week intervention in patients with gestational diabetes mellitus that received either vitamin D plus probiotic, probiotic
supplements or placebo.
Variables Placebo group (n ¼ 28) Probiotic group (n ¼ 29) Vitamin D plus
probiotic group
(n ¼ 30)
Difference in outcome
measures between
probiotic and placebo
groupsa
Difference in outcome
measures between vitamin
D plus probiotic and placebo
groupsc
Difference in outcome
measures between
vitamin D plus probiotic
and probiotic groupsd
Wk0 Wk6 Wk0 Wk6 Wk0 Wk6 b (95% CI) Pb b (95% CI) Pb b (95% CI) Pb
25-hydroxyvitamin
D (ng/mL)
14.3 ± 4.1 17.7 ± 3.7 12.9 ± 3.2 18.5 ± 3.1 13.4 ± 4.1 35.1 ± 3.9 2.05 (1.19, 2.91) <0.001 18.21 (17.36, 19.06) <0.001 16.16 (15.32, 17.00) <0.001
FPG (mg/dL) 94.1 ± 6.1 93.0 ± 7.9 96.6 ± 3.4 86.5 ± 7.6 95.4 ± 2.2 83.1 ± 5.7 8.60 (11.96,5.24) <0.001 10.99 (14.26,7.73) <0.001 2.39 (5.62,0.83) 0.14
Insulin (mIU/mL) 13.6 ± 2.5 13.4 ± 2.9 13.1 ± 7.7 11.7 ± 6.6 12.8 ± 4.6 10.8 ± 5.1 1.34 (2.46,0.22) 0.01 1.95 (3.05,0.84) 0.001 0.60 (1.70, 0.48) 0.27
HOMA-IR 3.1 ± 0.6 3.1 ± 0.8 3.1 ± 1.9 2.5 ± 1.5 3.0 ± 1.1 2.2 ± 1.1 0.54 (0.84,0.23) <0.001 0.76 (1.06,0.45) <0.001 0.22 (0.52, 0.08) 0.15
QUICKI 0.32 ± 0.009 0.32 ± 0.01 0.33 ± 0.03 0.34 ± 0.05 0.32 ± 0.01 0.34 ± 0.03 0.01 (0.00, 0.02) 0.05 0.01 (0.008, 0.03) 0.001 0.008 (0.003, 0.01) 0.14
Triglycerides (mg/dL) 157.2 ± 39.7 171.9 ± 42.6 160.6 ± 60.5 153.1 ± 60.5 170.5 ± 58.2 145.6 ± 53.4 21.73 (35.78,7.69) 0.003 37.56 (51.55,23.56) <0.001 15.82 (29.66,1.98) 0.02
VLDL-cholesterol (mg/dL) 31.4 ± 7.9 34.4 ± 8.5 32.1 ± 12.1 30.6 ± 12.1 34.1 ± 11.7 29.1 ± 10.7 4.34 (7.15,1.53) 0.003 7.51 (10.31,4.71) <0.001 3.16 (5.93,0.39) 0.02
Total cholesterol (mg/dL) 222.6 ± 40.8 225.8 ± 33.0 219.1 ± 36.4 219.6 ± 37.4 221.7 ± 39.1 215.4 ± 46.7 3.26 (15.68, 9.16) 0.60 9.63 (21.95, 2.67) 0.12 6.37 (18.58, 5.83) 0.30
LDL-cholesterol (mg/dL) 135.4 ± 36.6 136.9 ± 33.4 133.1 ± 34.2 134.9 ± 34.1 132.8 ± 35.7 128.4 ± 39.1 0.09 (10.98, 10.78) 0.98 6.30 (17.10, 4.49) 0.24 6.20 (16.90, 4.49) 0.25
HDL-cholesterol (mg/dL) 55.8 ± 14.8 54.5 ± 12.8 53.8 ± 12.0 54.1 ± 10.9 54.9 ± 10.7 57.9 ± 11.3 1.14 (1.86, 4.16) 0.45 4.09 (1.11, 7.08) 0.008 2.95 (0.005, 5.91) 0.05
Total-/HDL-cholesterol 4.2 ± 1.2 4.3 ± 1.2 4.2 ± 0.9 4.1 ± 0.8 4.1 ± 1.0 3.8 ± 0.8 0.19 (0.47, 0.08) 0.16 0.52 (0.79, 0.24) <0.001 0.32 (0.60, 0.05) 0.01
hs-CRP (mg/L) 5.2 ± 2.2 5.7 ± 2.2 5.4 ± 1.9 4.4 ± 1.3 6.2 ± 1.3 4.4 ± 1.3 1.36 (2.07,0.64) <0.001 1.80 (2.53,1.08) <0.001 0.44 (1.15, 0.26) 0.21
NO (mmol/L) 30.0 ± 4.1 29.8 ± 3.7 32.3 ± 4.5 33.0 ± 5.5 28.5 ± 5.1 29.4 ± 6.7 1.06 (0.74, 2.87) 0.24 1.00 (0.77, 2.77) 0.26 0.06 (1.90, 1.77) 0.94
TAC (mmol/L) 722.4 ± 140.9 704.2 ± 95.5 723.7 ± 226.7 739.7 ± 224.2 797.6 ± 80.2 860.2 ± 92.1 34.50 (10.44, 79.46) 0.13 97.77 (52.34, 143.19) <0.001 63.26 (18.25, 108.26) 0.006
GSH (mmol/L) 577.8 ± 260.3 577.4 ± 246.9 501.3 ± 59.9 511.9 ± 55.6 479.7 ± 100.6 548.8 ± 123.9 6.06 (59.92, 47.80) 0.82 47.55 (6.50, 101.62) 0.08 53.61 (1.56, 105.67) 0.04
MDA (mmol/L) 3.2 ± 0.9 3.4 ± 1.0 2.8 ± 0.6 2.7 ± 0.5 3.3 ± 0.6 3.1 ± 0.7 0.50 (0.85,0.16) 0.005 0.43 (0.77,0.09) 0.01 0.07 (0.26, 0.42) 0.65
Data are mean ±SDs.
FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, homeostasis model of assessment-insulin resistance; HDL-cholesterol, high density lipoprotein-cholesterol; Hs-CRP, high sensitivity C-reactive protein; LDL-
cholesterol, low density lipoprotein-cholesterol; MDA, malondialdehyde; NO, nitric oxide; QUICKI, quantitative insulin sensitivity check index; VLDL-cholesterol, very low density lipoprotein-cholesterol; SGA, subjective
global assessment; TAC, total antioxidant capacity.
a “Outcome measures” refers to the change in values of measures of interest between baseline and week 6. b [difference in the mean outcomes measures between treatment groups (probiotic group ¼ 1 and placebo
group ¼ 0)].
b Obtained from multiple regression model (adjusted for baseline values of each biochemical variables).
c “Outcome measures” refers to the change in values of measures of interest between baseline and week 6. b [difference in the mean outcomes measures between treatment groups (vitamin D plus probiotic group ¼ 1 and
placebo group ¼ 0)].
d “Outcome measures” refers to the change in values of measures of interest between baseline and week 6. b [difference in the mean outcomes measures between treatment groups (vitamin D plus probiotic group ¼ 1 and
probiotic group ¼ 0)].
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Table 4
The association of vitamin D plus probiotic supplementation with pregnancy outcomes.
Placebo group (n ¼ 28) Probiotic group (n ¼ 29) Vitamin Dþ probiotic group (n ¼ 30) Pb
Cesarean section (%) 12 (42.9) 10 (34.5) 7 (23.3) 0.28a
Preterm delivery (%) 1 (3.6) 1 (3.4) 0 (0.0) 0.58a
Pre-eclampsia (%) 5 (17.9) 3 (10.3) 2 (6.7) 0.39a
Polyhydramnios (%) 4 (14.3) 2 (6.9) 2 (6.7) 0.52a
Macrosomia>4000 g (%) 5 (17.9) 1 (3.4) 2 (6.7) 0.14a
Gestational age (weeks) 38.6 ± 1.1 38.9 ± 2.5 39.3 ± 0.8 0.25
Newborns' weight (g) 3176.4 ± 711.7 3170.7 ± 621.8 3308.3 ± 604.0 0.63
Newborns' length (cm) 49.9 ± 1.7 49.3 ± 3.7 48.7 ± 4.3 0.42
Newborns' head circumference (cm) 35.4 ± 1.5 35.2 ± 2.6 36.2 ± 2.8 0.27
1- min Apgar score 8.8 ± 0.5 8.9 ± 0.3 8.9 ± 0.2 0.28
5- min Apgar score 9.7 ± 0.5 9.9 ± 0.3 9.9 ± 0.2 0.28
Newborns' hyperbilirubinemia (%) 10 (35.7) 4 (13.8) 3 (10.0) 0.03a
Newborns' hospitalization (%) 9 (32.1) 3 (10.3) 3 (10.0) 0.04a
Newborns' hypoglycemia (%) 4 (14.3) 3 (10.3) 3 (10.0) 0.85a
Values are means ± SDs for continuous measures and are number (%) for dichotomous variables.
a Obtained from Pearson Chi-square test.
b Obtained from ANOVA test.
M. Jamilian et al. / Clinical Nutrition xxx (xxxx) xxx6ratio, and signiﬁcantly increased HDL-cholesterol, but did not inﬂu-
ence total- and LDL-cholesterol levels in patients with GDM. Simi-
larly, probiotic intake in patients with T2DM reduced triglycerides
and increased HDL-cholesterol levels [33]. Moreover, vitamin D
supplementation to patients with obstructive sleep apnea for 15
weeks increased HDL-cholesterol levels [34]. Increased triglycerides
and free fatty acids concentrations in women with GDM are corre-
lated with accelerated fetal growth during pregnancy presented as
greater neonatal anthropometric measures [35]. On the other hand,
abnormal maternal lipid proﬁles might be correlated with serious
complications such as macrosomia [36], pre-eclampsia and preterm
birth [37]. Probiotic consumption inﬂuences intestinal bacteria
composition and may improve carbohydrate and lipid metabolism
by increasing glucagon like peptid-1 secretion, suppression of the toll
like reseptor-4 signaling pathway, and modulating the peroxisome
proliferator-activated receptor-g [38]. In addition, vitamin D en-
hances b-cell function via vitamin D receptors, induce insulin
sensitivity and alleviate chronic inﬂammation which is involved in
the developing of insulin resistance [39].
4.2. Effects on biomarkers of inﬂammation and oxidative stress
Previous evidence has reported elevated circulating inﬂamma-
tory markers and decreased antioxidant defense in women with
GDM [40]. We found that vitamin D and probiotic co-
supplementation, compared with the placebo, signiﬁcantly
reduced hs-CRP and MDA, and signiﬁcantly increased TAC, but did
not affect NO and GSH levels. In agreement with our ﬁndings,
supplementation with vitamin D plus L. reuteri to children with
allergic asthma for 90 days reduced bronchial inﬂammation [41]. In
addition, taking vitamin D supplementation by diabetic patients
with coronary artery disease decreased hs-CRP and MDA levels
[42]. However, in adolescents with T1DM and vitamin D deﬁciency,
vitamin D administration did not improve inﬂammatory markers
[43]. Furthermore, taking probiotic product enriched with iso-
ﬂavones in moderately hypercholesteromic males did not improve
CRP levels [44]. One of the main reasons for insulin resistance in
GDMmight be antioxidant imbalance [45]. Moreover, inﬂammation
can increase the incidence of maternal cardiovascular disease in
later life [46]. Oxidative stress and related toxic products can
damage biological molecules which increases the susceptibility of
offspring to chronic disease [4,47]. Existing experimental studies
have shown that antioxidant supplementationmay improve insulin
sensitivity and decrease GDM complications [48]. Vitamin D and
probiotic, with anti-inﬂammatory and anti-oxidative properties,
may be useful to reduce the complications related to GDM. ShortPlease cite this article as: Jamilian M et al., The effects of vitamin D and p
oxidative stress and pregnancy outcomes in gestational diabetes: A ra
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on inﬂammation and oxidative stress via modulating the G-protein
coupled receptor43 and inducing hydroxyl radical scavenging ac-
tivity which inhibit lipid peroxidation [49]. In addition, vitamin D
reduces gene expression of pro-inﬂammatory mediators and given
the effects on T-regulatory cells, probably modiﬁes the effects of gut
microbiome on the immune system and inﬂammation [50].
4.3. Effects on pregnancy outcomes
In the current study, vitaminD plus probiotic co-supplementation
signiﬁcantly reduced the incidence of newborn's hyperbilirubinemia
and hospitalization in comparison to only probiotic and placebo, but
did not affect other outcomes. Inconsistent to present data, our prior
researches indicated that synbiotic supplementation [51] and cal-
cium plus vitamin D administration [52] in women with GDM
decreased the incidence of neonates' hyperbilirubinemia and hos-
pitalization. Decreased incidence of newborn's hyperbilirubinemia
and newborns' hospitalization may be due to improved metabolic
proﬁles. Although we agree that further studies are needed to
explore such possible mechanisms.
Some limitations need to be taken into account in the inter-
pretation of our ﬁndings. Due to funding limitations, we did not
characterize the microbiota and thus cannot establish whether
probiotic administration over 6 weeks changed its composition. In
addition, we did not examine the effects of vitamin D and probiotic
supplementation on gene expression related to metabolic proﬁles.
4.4. Conclusions
In conclusion, vitamin D and probiotic co-supplementation led
to signiﬁcant improvements in glycemic control, lipids concentra-
tions except total- and LDL-cholesterol, and hs-CRP, TAC, GSH and
MDA levels, incidence of newborn's hyperbilirubinemia and new-
borns' hospitalization, but did not affect other metabolic proﬁles
and pregnancy outcomes.
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